Skip to content

Clinical Study on Rumu Zhitong Ointment for Treating Cancer Pain via Acupoint Selection Along Meridians Combined with Plaster Application

Clinical Study on Rumu Zhitong Ointment for Treating Cancer Pain via Acupoint Selection Along Meridians Combined with Plaster Application

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002421
Enrollment
Unknown
Registered
2025-12-10
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

Experimental Group:On the basis of conventional medication, the experimental group received combined meridian-guided acupoint selection and topical application of Olibanum-Myrrh Analgesic Ointment. A
Control Group:On the basis of conventional medication, the control group received topical application of Olibanum-Myrrh Analgesic Ointment at the Ashi point (pain site). Only a 5cm×7cm large patch (we

Sponsors

Beijing Traditional Chinese Medicine Hospital Yanqing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Patients with pathologically confirmed malignant tumors; 2) According to the NCCN Clinical Practice Guidelines for Adult Cancer Pain (2019.V1)and the WHO Guidelines for Cancer Pain Relief: Stepped Care Approach, the etiology of cancer pain must be directly caused by the tumor (including pain from primary and/or metastatic tumors), with a pain score =1; 3) Fixed pain location; no skin breakdown, redness, swelling, or heat in the affected area; 4) Pain characterized as persistent cold pain, stabbing pain, worse at night, alleviated by warmth; TCM local syndrome differentiation indicates a yin syndrome; 5) Age =18 years; 6) Normal verbal communication ability, capable of assessing their own pain and general condition, and able to cooperate in evaluating pain and quality of life; 7) Informed of the treatment details, agreed to participate, and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Pain associated with oncologic emergencies; 2) Pain caused by trauma, obstruction, or other non-tumor-related factors; 3) Patients unable to comply with the study treatment requirements; 4) Patients with severe cardiac, hepatic, or renal dysfunction; 5) Patients allergic to opioid analgesics; 6) Patients with severe intellectual or psychiatric disorders; 7) Pain originating from primary tumors or tumor-invasive sites not corresponding to the twelve meridians.

Design outcomes

Primary

MeasureTime frame
Pain Score;Quality of Life Score;Onset Time and Duration of Efficacy;TCM Syndrome;

Secondary

MeasureTime frame
Opioid use;Anxiety Inventory;

Countries

China

Contacts

Public ContactShuangwen Liu

Beijing Traditional Chinese Medicine Hospital Yanqing Hospital

13522236916@163.com13522236916

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026